New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30-June 3, 2025, in Chicago. This includes the latest findings from Castle's ongoing collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (NCI's SEER) Program Registries affirming the significant, independent risk stratification provided by DecisionDx-Melanoma in an expanded, real-world cohort of more than 13,500 patients who received the test as part of their melanoma care.
'Management decisions for melanoma patients, such as referrals for sentinel lymph node biopsy and surveillance intensity, are guided by a patient's risk of dying from their disease,' said Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. 'The findings being presented at ASCO demonstrate that the DecisionDx-Melanoma test can provide more precise mortality risk predictions based on a patient's unique tumor biology and can improve upon the population-based risk assessment provided by American Joint Committee on Cancer (AJCC) staging. This can, in turn, help clinicians tailor treatment approaches to individual patient needs.'
Castle's presentations at ASCO will take place during the Melanoma/Skin Cancers poster session on Sunday, June 1, from 9 a.m. to 12 p.m. Central time in Hall A – Posters and Exhibits. Title: The 31-gene expression profile can guide better risk-aligned care decisions for patients with stage I–III cutaneous melanoma: an NCI-SEER analysis
Abstract: 9573
Poster Bd #: 56
Lead Author: Merve Hasanov, M.D., oncologist and director of the division of medical oncology at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Study highlights : This study presents an updated validation of the DecisionDx-Melanoma test's ability to independently stratify CM patients' mortality risk within AJCC sub-stages (stages I-IIA, IIB-C and III) as part of Castle's ongoing collaboration with the NCI's SEER Program Registries. In this large, real-world cohort of 13,560 patients with CM – the largest real-world study of gene expression profile testing to date – the test provided significant risk stratification within the AJCC sub-groups (p<0.001). In multivariable analysis that included key AJCC staging criteria (i.e., Breslow thickness, ulceration and nodal status) and other commonly used clinicopathologic risk factors (e.g., age and mitotic rate), DecisionDx-Melanoma test results emerged as a significant predictor of melanoma-specific mortality (Class 2B hazard ratio=4.59, p<0.001; Class 1B/2A hazard ratio=3.42, p<0.001). Further, testing with DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients, providing further evidence of the test's association with improved patient survival and affirming the test's potential to inform risk-aligned treatment pathway decisions that may lead to improved patient outcomes. 1
: This study presents an updated validation of the DecisionDx-Melanoma test's ability to independently stratify CM patients' mortality risk within AJCC sub-stages (stages I-IIA, IIB-C and III) as part of Castle's ongoing collaboration with the NCI's SEER Program Registries. In this large, real-world cohort of 13,560 patients with CM – the largest real-world study of gene expression profile testing to date – the test provided significant risk stratification within the AJCC sub-groups (p<0.001). In multivariable analysis that included key AJCC staging criteria (i.e., Breslow thickness, ulceration and nodal status) and other commonly used clinicopathologic risk factors (e.g., age and mitotic rate), DecisionDx-Melanoma test results emerged as a significant predictor of melanoma-specific mortality (Class 2B hazard ratio=4.59, p<0.001; Class 1B/2A hazard ratio=3.42, p<0.001). Further, testing with DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients, providing further evidence of the test's association with improved patient survival and affirming the test's potential to inform risk-aligned treatment pathway decisions that may lead to improved patient outcomes. Title: Independent validation of a 16-protein test to assess malignant potential of small uveal melanocytic tumors
Abstract: 9590
Poster Bd #: 73
Lead Author and Presenter: David Alan Reichstein, M.D., retina specialist and ocular oncologist at Tennessee Retina, Nashville, Tennessee
Study highlights: UM is a rare but aggressive eye cancer with up to 50% of patients developing metastatic disease. While tumor biopsy-based molecular testing (i.e., DecisionDx-UM) is widely utilized to identify high-risk biology, repeated intraocular tumor biopsies are not feasible for monitoring small uveal melanocytic tumors of indeterminate malignant potential (UMTIMP). This multicenter study explored a novel diagnostic approach designed to analyze protein biomarkers in aqueous humor (AH) obtained through minimally invasive, in-office liquid biopsy of the anterior chamber of the eye. In the independent validation, the 17-biomarker test that evaluates 16 proteins and tumor diameter information successfully distinguished between low- and high-risk UM lesions with a sensitivity of 91%, specificity of 50%, negative predictive value of 92% and positive predictive value of 47%. If developed, this high-sensitivity test could help to accurately identify high-risk melanocytic lesions that would merit more invasive intraocular biopsy and further prognostic testing with DecisionDx-UM, -PRAME and -UM Seq . The study findings support a liquid biopsy approach to monitor suspicious UMTIMPs for malignant transformation to inform more timely decision-making and earlier therapeutic interventions to help improve patient outcomes.
The full abstracts outlined above can be found at the ASCO website here. For more information regarding Castle's data at ASCO, please visit booth # 24149.
About DecisionDx-Melanoma
DecisionDx-Melanoma is a 31-gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient's individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma's clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test's results. Through March 31, 2025, DecisionDx-Melanoma has been ordered more than 200,000 times for patients diagnosed with cutaneous melanoma.
About DecisionDx-UM
DecisionDx-UM is Castle Biosciences' 15-gene expression profile (GEP) test that uses an individual patient's tumor biology to predict individual risk of metastasis in patients with uveal melanoma (UM). DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States. Since 2009, the American Joint Committee on Cancer (AJCC; v7 and v8) Staging Manual for UM has specifically identified the GEP test as a prognostic factor that is recommended for collection as a part of clinical care. Further, the National Comprehensive Cancer Network (NCCN) guidelines for UM include the DecisionDx-UM test result as a prognostic method for determining risk of metastasis and recommended differential surveillance regimens based on a Class 1A, 1B and 2 result. DecisionDx-UM is currently the only prognostic test for UM that has been validated in prospective, multi-center studies, and it has been shown to be a superior predictor of metastasis compared to other prognostic factors, such as chromosome 3 status, mutational status, AJCC stage and cell type. It is estimated that nearly 8 in 10 patients diagnosed with UM in the United States receive the DecisionDx-UM test as part of their diagnostic workup.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the significant, independent risk stratification provided by DecisionDx-Melanoma; DecisionDx-Melanoma's ability to (i) provide more precise mortality risk predictions and improve upon population-based risk assessment provide by AJCC staging, (ii) be a significant predictor of melanoma-specific mortality and (iii) improve patient survival and lead to improved patient outcomes; and DecisionDx-UM's ability to help accurately identify high-risk melanocytic lesions and improve patient outcomes. The words 'believe,' 'can' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report for the three months ended March 31, 2025 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law. Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. JCO Precis. Oncol . 2023; 7. doi: 10.1200/PO.23.00044
Investor Contact:Camilla Zuckero
[email protected]
Media Contact:Allison Marshall
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Should You Forget Tesla and Buy This Millionaire-Maker Stock Instead?
Key Points Shares of Rocket Lab USA have soared more than 50% year to date. The rise of space infrastructure is a long-term trend now unfolding. It will pick up speed as space travel becomes cheaper and more reliable. 10 stocks we like better than Rocket Lab › Is it time to move on from Tesla stock? After the first six months of 2025, many investors might be tempted to do so. As of this writing, shares of the electric vehicle maker are down 22%, leaving many investors very disappointed. While I'm not prepared to move on from Tesla, there are other innovative companies that investors should keep an eye on. Today, I want to cover one of them, Rocket Lab USA (NASDAQ: RKLB). Unlike Tesla, its shares have been on fire so far this year, with a year-to-date return of more than 60%. Here's what you need to know about the company and its stock. Rocket Lab USA The first question investors should ask is: What exactly does Rocket Lab USA do? Well, it's a leader in the field of rocketry and orbital deployments. The company partners with governmental and commercial organizations to send up satellites and other space-based assets into orbit. Like its better-known competitor, SpaceX, Rocket Lab is riding a fast-growing trend: the expansion of space infrastructure. In short, the need for more high-tech equipment in space is increasing as governments and businesses alike turn skyward. Everything from logistics tracking to farming can now incorporate orbital technology, and Rocket Lab is stepping up by expanding access to orbital launches. The company has already completed 10 successful launches of its Electron rocket this year, bringing its total to 68 overall. What's more, the company is progressing toward the use of its reusable Neutron rocket. That program aims to further expand Rocket Lab's overall launch profile by incorporating a reusable rocket (Neutron), which then lands on a 400-foot landing platform. By integrating reusable rocketry, RocketLab aims to lower launch costs, making space-based infrastructure more affordable -- and appealing -- to a growing list of organizations. As the company continues to ramp up launches, its financials are poised to improve. Over the past 12 months, Rocket Lab has generated $466 million in revenue, up 32% year over year. As the company's Neutron program comes online, Rocket Lab's revenue growth should accelerate. According to consensus estimates compiled by Yahoo! Finance, sell-side analysts expect Rocket Lab to generate $890 million in revenue in 2026, up 55% from 2025. Yet, investors should know that Rocket Lab stock does carry risks. For starters, the company is unprofitable and lacks positive free cash flow. Second, any setback in its operations due to a launch malfunction could delay future missions, putting pressure on the company's balance sheet. While Rocket Lab has over $428 million in cash on hand, it also has $490 million in debt. That means the company may need to raise further capital to service its debt and continue operations. Therefore, Rocket Lab stock isn't for every investor. As a high-flying stock -- in every sense of the phrase -- Rocket Lab may be too hot to handle for some investors. Nevertheless, for investors who are willing to hold through volatility, Rocket Lab offers a chance to invest in the next great adventure for humankind: space. It's clear that humanity will want to achieve more in space in the decades to come, and for that to happen, reliable and cheap transportation to space will be necessary. Rocket Lab is well-positioned to be one of the early leaders in this field. Investors should take notice. Should you buy stock in Rocket Lab right now? Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,281!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,050,415!* Now, it's worth noting Stock Advisor's total average return is 1,059% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Jake Lerch has positions in Rocket Lab and Tesla. The Motley Fool has positions in and recommends Rocket Lab and Tesla. The Motley Fool has a disclosure policy. Should You Forget Tesla and Buy This Millionaire-Maker Stock Instead? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Why Sensus Healthcare, Inc. (SRTS) Outpaced the Stock Market Today
In the latest close session, Sensus Healthcare, Inc. (SRTS) was up +2.54% at $4.44. The stock's change was more than the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw an increase of 0.74%. Prior to today's trading, shares of the company had lost 8.65% lagged the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%. The investment community will be closely monitoring the performance of Sensus Healthcare, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of $0.01, indicating a 90% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.8 million, down 4.76% from the year-ago period. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.11 per share and a revenue of $41.95 million, indicating changes of -73.17% and +0.34%, respectively, from the former year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Sensus Healthcare, Inc. is currently sporting a Zacks Rank of #4 (Sell). Investors should also note Sensus Healthcare, Inc.'s current valuation metrics, including its Forward P/E ratio of 39.36. This indicates a premium in contrast to its industry's Forward P/E of 22.47. The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 35% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sensus Healthcare, Inc. (SRTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Medical device software developer Heartflow files for US IPO
(Reuters) -Heartflow, an artificial intelligence-based medical device software developer, filed for an initial public offering in the United States on Thursday. The U.S. IPO market is witnessing a renewed vigor as investors return following months of sluggish activity triggered by trade policy uncertainty under President Donald Trump, earlier this year. Heartflow will list on the Nasdaq under the symbol "HTFL". J.P. Morgan, Morgan Stanley and Piper Sandler are among the underwriters for the offering. Sign in to access your portfolio
